Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Common Equity (2018 - 2025)

Historic Common Equity for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $157.2 million.

  • Whitehawk Therapeutics' Common Equity rose 12821.63% to $157.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.2 million, marking a year-over-year increase of 12821.63%. This contributed to the annual value of $52.5 million for FY2024, which is 5011.36% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Common Equity stood at $157.2 million, which was up 12821.63% from $172.1 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Common Equity's 5-year high stood at $221.7 million during Q1 2025, with a 5-year trough of $35.2 million in Q2 2021.
  • In the last 5 years, Whitehawk Therapeutics' Common Equity had a median value of $124.6 million in 2022 and averaged $119.2 million.
  • In the last 5 years, Whitehawk Therapeutics' Common Equity skyrocketed by 21929.57% in 2022 and then crashed by 5011.36% in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Common Equity (Quarter) stood at $136.4 million in 2021, then increased by 16.11% to $158.4 million in 2022, then crashed by 33.58% to $105.2 million in 2023, then plummeted by 50.11% to $52.5 million in 2024, then skyrocketed by 199.49% to $157.2 million in 2025.
  • Its last three reported values are $157.2 million in Q3 2025, $172.1 million for Q2 2025, and $221.7 million during Q1 2025.